@article{e0984fda5ac84ff8b2847af6a99945d1,
title = "Safety and Efficacy of Nivolumab in Patients With Advanced Non–small-cell Lung Cancer Treated Beyond Progression: Clinical Lung Cancer",
keywords = "Nivolumab, NSCLC, Pseudoprogression, RECIST, Treatment beyond progression, alanine aminotransferase, alkaline phosphatase, anaplastic lymphoma kinase, aspartate aminotransferase, bilirubin, epidermal growth factor receptor, gamma glutamyltransferase, nivolumab, abdominal pain, adult, advanced cancer, aged, anemia, anorexia, arthralgia, Article, cancer fatigue, cancer growth, cancer immunotherapy, cancer staging, cancer survival, colitis, constipation, controlled study, dermatomyositis, disease association, disease control, drug efficacy, drug safety, drug withdrawal, dry skin, female, human, hyperthyroidism, hypothyroidism, kidney failure, major clinical study, male, nausea, neutropenia, non small cell lung cancer, overall survival, pneumonia, progression free survival, psoriasis, rash, response evaluation criteria in solid tumors, side effect, thrombocytopenia, treatment duration, uveitis, vomiting, xerostomia",
author = "B. Ricciuti and C. Genova and M. Bassanelli and {De Giglio}, A. and M. Brambilla and G. Metro and S. Baglivo and {Dal Bello}, M.G. and A. Ceribelli and F. Grossi and R. Chiari",
note = "Export Date: 30 January 2020 CODEN: CLCLC Correspondence Address: Ricciuti, B.; Department of Medical Oncology, Thoracic Oncology Unit, Santa Maria della Misericordia Hospital, University of Perugia, Piazzale Menghini, Italy; email: biagio.ricciuti@gmail.com",
year = "2019",
doi = "10.1016/j.cllc.2019.02.001",
language = "English",
volume = "20",
pages = "178--185.e2",
journal = "Clin. Lung Cancer",
issn = "1525-7304",
publisher = "Elsevier Inc.",
number = "3",
}